Checkmate 901 Study News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Checkmate 901 Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Checkmate 901 Study Today - Breaking & Trending Today

Frontline Nivolumab Plus Chemotherapy Boosts OS and PFS in Metastatic Urothelial Carcinoma

Published: October 22, 2023

Concurrent frontline nivolumab and gemcitabine-cisplatin followed by nivolumab maintenance therapy elicited OS and PFS benefits vs gemcitabine-cisplatin alone in patients with previously untreated, metastatic or unresectable urothelial carcinoma.

Source: onclive.com

Related Topics:

Noord HollandMichiels VanNetherlands Cancer InstituteConcurrent Frontline Nivolumab And Gemcitabine CisplatinUrothelial CarcinomaCheckmate 901 StudyMichiels Van Der Heijden